In 2002, Steinbach et al. (Steinbach et al. 2002) showed that the PRAME gene was expressed by CD34+ stem cells which they suggested may constitute a problem for its targeting in tumor immunotherapy. This evidence concerns the gene PRAME and neoplasm.